Zacks Investment Research Lowers Omnicell (OMCL) to Sell
Omnicell (NASDAQ:OMCL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Omnicell's weak margin scenario is a matter of concern. The company lowering the high end of the full-year 2017 adjusted revenue guidance is indicative of this overall dull scenario to remain. A tough competitive landscape also acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry. However, on a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all its business lines in the quarter. We are encouraged to note that the company is working on product innovation through R&D. Over the recent past, Omnicell has been observed to gain consistently from series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships.”
Other equities analysts have also issued reports about the company. Cantor Fitzgerald restated a “buy” rating and set a $60.00 price target on shares of Omnicell in a research note on Tuesday, December 5th. BidaskClub lowered Omnicell from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. Oppenheimer restated a “buy” rating and set a $55.00 price target on shares of Omnicell in a research note on Thursday, October 19th. Finally, Craig Hallum restated a “buy” rating and set a $62.00 price target (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $55.14.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The company had revenue of $186.78 million during the quarter, compared to analysts’ expectations of $192.45 million. During the same quarter in the previous year, the firm earned $0.40 earnings per share. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. equities analysts forecast that Omnicell will post 0.12 earnings per share for the current fiscal year.
In other Omnicell news, VP Peter J. Kuipers sold 4,724 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the transaction, the vice president now owns 40,544 shares of the company’s stock, valued at approximately $1,935,570.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Jorge R. Taborga sold 6,295 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $48.69, for a total value of $306,503.55. Following the transaction, the vice president now directly owns 50,013 shares in the company, valued at approximately $2,435,132.97. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,558 shares of company stock worth $1,330,230. Company insiders own 3.77% of the company’s stock.
Large investors have recently bought and sold shares of the business. BlackRock Inc. raised its position in shares of Omnicell by 2.3% during the 2nd quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock valued at $197,790,000 after acquiring an additional 101,776 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Omnicell by 3.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock valued at $83,105,000 after buying an additional 67,902 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Omnicell by 0.7% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock valued at $82,584,000 after buying an additional 11,105 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Omnicell by 129.6% in the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock valued at $53,096,000 after buying an additional 695,334 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its position in shares of Omnicell by 14.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 998,107 shares of the company’s stock valued at $52,200,000 after buying an additional 127,873 shares in the last quarter. 99.61% of the stock is currently owned by hedge funds and other institutional investors.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.